US9956227 — Method for the treatment of residual symptoms of schizophrenia
Method of Use · Assigned to Intra Cellular Therapies Inc · Expires 2034-12-03 · 9y remaining
What this patent protects
This patent protects the use of certain compounds for treating residual symptoms of psychosis or schizophrenia, including long-acting injectable formulations.
USPTO Abstract
The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-2714 |
— | lumateperone-tosylate |
U-2714 |
— | lumateperone-tosylate |
U-2714 |
— | lumateperone-tosylate |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.